SCHEMBL6913073

SCHEMBL6913073

O=c1[nH]nc2c3ccccc3n(Cc3ccc(Br)cn3)cc1-2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 8/20 0.64
PDE4B Q07343 8/20 0.64
PDE4C Q08493 8/20 0.64
PDE4D Q08499 8/20 0.64
PDE3B Q13370 6/20 0.64
PDE3A Q14432 6/20 0.64
CHRM1 P11229 4/20 0.53
GRM2 Q14416 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914077 0.76 PDE4A (0.53) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL11895927 0.74 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL11896033 0.74 CHRM1 (0.47) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL11895466 0.74 CHRM1 (0.48) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL11895817 0.74 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL17338019 0.73 PDE4B (0.68) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL17337964 0.72 PDE4A (0.65) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL17337965 0.71 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL17338005 0.70 CNR2 (0.64) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL11894855 0.70 CHRM1 (1.00) PDE4APDE4BPDE4CPDE4DPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2490692-B1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2016-11-16 EP disclosed
US-8895580-B2 Quinolinone-pyrazolone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-11-25 US disclosed
US-20120196845-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2012-08-02 US disclosed
WO-2011049731-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196845-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRL1, CHRNA5 PDE4A 368/4885PDE4B 471/4885PDE4C 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.